Validation of the 12-gene colon cancer recurrence score (RS) in NSABP C07 as a predictor of recurrence in stage II and III colon cancer patients treated with 5FU/LV (FU) and 5FU/LV+oxaliplatin (FU plus Ox).

被引：0
|
作者：
O'Connell, Michael
Lee, Mark
Lopatin, Margarita
Yothers, Greg
Clark-Langone, Kim
Millward, Carl
Paik, Soonmyung
Sharif, Saima
Shak, Steven
Wolmark, Norman
机构：
[1] Natl Surg Adjuvant Breast & Bowel Project, Pittsburgh, PA USA
[2] Genom Hlth, Redwood City, CA USA
[3] NSABP Biostat Ctr, Pittsburgh, PA USA
[4] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA
[5] Allegheny Gen Hosp, Pittsburgh, PA 15212 USA
[6] Allegheny Gen Hosp, Allegheny Canc Ctr, Pittsburgh, PA 15212 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3512
引用
收藏
页数：1
相关论文
共 50 条
  • [1] THE 12-GENE COLON CANCER RECURRENCE SCORE (RS) PREDICTS RECURRENCE IN STAGE II AND III COLON CANCER PATIENTS TREATED WITH 5FU/LV (FU) AND 5FU/LV plus OXALIPLATIN (FU+OX): VALIDATION IN NSABP C07
    O'Connell, M. J.
    Lee, M.
    Lopatin, M.
    Yothers, G.
    Clark-Langone, K. M.
    Millward, C.
    Paik, S.
    Sharif, S.
    Shak, S.
    Wolmark, N.
    ANNALS OF ONCOLOGY, 2012, 23 : 179 - 180
  • [2] Validation of the 12-Gene Colon Cancer Recurrence Score in NSABP C-07 As a Predictor of Recurrence in Patients With Stage II and III Colon Cancer Treated With Fluorouracil and Leucovorin (FU/LV) and FU/LV Plus Oxaliplatin
    Yothers, Greg
    O'Connell, Michael J.
    Lee, Mark
    Lopatin, Margarita
    Clark-Langone, Kim M.
    Millward, Carl
    Paik, Soonmyung
    Sharif, Saima
    Shak, Steven
    Wolmark, Norman
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (36) : 4512 - +
  • [3] Validation of the 12-Gene Colon Cancer Recurrence Score in NSABP C-07 As a Predictor of Recurrence in Patients With Stage II and III Colon Cancer Treated With Fluorouracil and Leucovorin (FU/LV) and FU/LV Plus Oxaliplatin (vol 31, pg 4512, 2013)
    Yothers, Greg
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (08) : 866 - 866
  • [4] Stage II patients in the "MOSAIC" trial evaluating Oxaliplatin/5FU/LV as adjuvant treatment of colon cancer: a subpopulation analysis
    Hickish, Tamas
    Boni, Corrado
    Navarro, Matilde
    Tabernero, Josep
    Bonetti, Andrea
    Clingan, Philip
    Figer, Arie
    Andre, Thierry
    de Gramont, Aimery
    ANNALS OF ONCOLOGY, 2004, 15 : 76 - 76
  • [5] Cost-Effectiveness of Adjuvant FOLFOX and 5FU/LV Chemotherapy for Patients with Stage II Colon Cancer
    Ayvaci, Mehmet U. S.
    Shi, Jinghua
    Alagoz, Oguzhan
    Lubner, Sam J.
    MEDICAL DECISION MAKING, 2013, 33 (04) : 521 - 532
  • [6] Oxaliplatin/5FU/LV in stage II and III Colon Cancer: Updated results (as of January 04) for efficacy and neurotoxicity of the MOSAIC trial
    de Gramont, Aimery
    Boni, Corrado
    Navarro, Matilde
    Tabernero, Josep
    Hickish, Tamas
    Topham, Clare
    Bonetti, Andrea
    Clingan, Philip
    Marceau-Suissa, Jeanne
    Andre, Thierry
    ANNALS OF ONCOLOGY, 2004, 15 : 73 - 73
  • [7] A prospective pharmacogenetic study of 5FU/LV in high-risk stage II and III colon cancer patients.
    Mulder, K
    Scarfe, AG
    Koski, S
    Au, HJ
    Butts, C
    Fields, A
    Razavy, H
    Graham, K
    Cass, CE
    Sawyer, MB
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 143S - 143S
  • [8] Patient-specific meta-analysis of 12-gene colon cancer recurrence score validation studies for recurrence risk assessment after surgery with or without 5FU and oxaliplatin
    Yothers, Greg
    Venook, Alan P.
    Oki, Eiji
    Niedzwiecki, Donna
    Lin, Yan
    Crager, Michael R.
    Chao, Calvin
    Baehner, Frederick L.
    Wolmark, Norman
    Yoshino, Takayuki
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 13 (01) : 126 - +
  • [9] Randomized phase III trial comparing 5FU bolus and low dose leucovorin versus 5FU bolus plus continuous 5FU infusion and high dose LV in metastatic colorectal cancer
    Bosset, JF
    DeGrammont, A
    Milan, C
    Rougier, P
    Bouche, O
    Etienne, PL
    Morvan, F
    Louvet, C
    Guillot, T
    Bedenne, L
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 702 - 702
  • [10] Economic evaluation of adjuvant chemotherapy in Stage III (SIII) colon cancer: Capecitabine versus 5FU/LV.
    Virik, K.
    Skedgel, C.
    Younis, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 312S - 312S
12345